AIMP2 Antibody

AIMP2, short for aminoacyl tRNAse synthetase complex-interacting multifunctional protein 2, is also called JTV1 and first identified as the p38 component of the macromolecular complex of tRNA synthetases (1). Along with AIMP1 and AIMP3, AIMP2 forms a trio of auxiliary proteins bound to the aminoacyl tRNase synthetase complex. AIMP1 has already been identified as a pleiotropic cytokine that enhances TLR1, TLR2, TLR3 and TLR7 expression in BM-DCs. AIMP1 also enhances DC production of IL-6 and IL-12 and increases NF-kB activity (2). AIMP2 appears to enhance TNFa induced apoptosis via degradation of TRAF2 (3). It also counters proliferative effects of TGFb imparted by down regulation of c-Myc (3). Reduction of AIMP2 levels in AIMP2 heterozygous or homozygous mice led to higher susceptibility to tumor growth. AIMP2 levels being inversely proportion to the apoptotic process, proliferation and tumorigenesis, implicate AIMP2 as a tumor suppressor. Taken together with the finding that AIMP1 and AIMP3 mutations or allelic deletions are reported in cancer patients (4) (and perhaps similarly AIMP2 as well) bolster the concept of AIMP2 as a potential target for its enhanced expression in development of anti-cancer reagents.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Array NBP2-27094

• AIMP2 Antibodies
• AIMP2 Lysate
• AIMP2 Proteins